Sign In
Free Newsletter
Merck’s $680M Harpoon acquisition to diversify oncology pipeline
According to Dr. Dean Li, president, Merck Research Laboratories, “This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon," a South San Francisco-based clinical-stage immunotherapy company.
Newsweek names Merck America’s most responsible company (updated)
In total, 18 firms from New Jersey were included in the rankings, which were based on corporations' “holistic view of corporate responsibility, as defined by ESG measures such as environment, social good and corporate governance."
Merck to acquire Caraway Therapeutics for up to $610M
The Cambridge, Mass.-based target works on treatments for neurodegenerative and rare diseases, including Parkinson's disease and ALS.
Merck Foundation gifts $14M for children’s facility expansion
The Inn at the National Institutes of Health in Bethesda, Md., offers therapeutic, educational and recreational programming at no cost to young patients and families from around the country and the world.
NJ drugmakers’ products among first targeted for Medicare price negotiations
Pharmaceutical companies, including Merck, Johnson & Johnson and others, are concerned the move will hamper innovation and impede patient access and choice.
Despite challenges, ‘capital is always available for good ideas’
Continued turbulence in the financial markets and headwinds from legislation aimed at capping drug costs haven't dampened spirits at some New Jersey enterprises.
Merck officially opens ‘reimagined’ Rahway headquarters
“This is a big day,” Gov. Phil Murphy said June 20. “It’s a big day for Merck, I get that. But it’s a big day for Jersey. This validates what we are about, who we are about. We have the highest concentration of scientists and engineers per square mile of anywhere in the world. And this campus speaks directly to that.”
Merck finalizes $10.8B Prometheus acquisition
Robert Davis, chairman and CEO of the Rahway-based buyer, said the deal "accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value."
Merck to acquire San Diego biotech company for $10.8B
“The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need,” Merck Chairman and CEO Robert Davis said in a statement.
FDA clears Merck’s Keytruda for expanded use
The move is the first full approval for an immunotherapy based on a predictive biomarker. In 2022, the best-selling cancer treatment's sales grew 22% to $20.9 billion.
Merck to close $1.35B Imago acquisition
On Jan. 11, the Rahway-headquartered pharmaceutical giant said it completed its cash tender offer for all of the outstanding shares of common stock of the California-based biopharmaceutical company.
Merck commits $5M to joint pan-African Transform Health Fund
“Since our company’s founding, we have been committed to advancing global health and using the power of science to save and improve lives,” company Chairman and CEO Robert Davis said.
